AU2015243694B2 - (5,6-dihydro)pyrimido(4,5-e)indolizines - Google Patents

(5,6-dihydro)pyrimido(4,5-e)indolizines Download PDF

Info

Publication number
AU2015243694B2
AU2015243694B2 AU2015243694A AU2015243694A AU2015243694B2 AU 2015243694 B2 AU2015243694 B2 AU 2015243694B2 AU 2015243694 A AU2015243694 A AU 2015243694A AU 2015243694 A AU2015243694 A AU 2015243694A AU 2015243694 B2 AU2015243694 B2 AU 2015243694B2
Authority
AU
Australia
Prior art keywords
carboxamide
indolizine
anilino
methoxy
dihydropyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015243694A
Other languages
English (en)
Other versions
AU2015243694A1 (en
Inventor
Rogier Christian Buijsman
Adrianus Petrus Antonius De Man
Joeri Johannes Petrus DE WIT
Jan Gerard STERRENBURG
Joost Cornelis Marinus UITDEHAAG
Guido Jenny Rudolf Zaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sillajen Inc
Original Assignee
SILLAJEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SILLAJEN Inc filed Critical SILLAJEN Inc
Publication of AU2015243694A1 publication Critical patent/AU2015243694A1/en
Application granted granted Critical
Publication of AU2015243694B2 publication Critical patent/AU2015243694B2/en
Assigned to SillaJen Inc. reassignment SillaJen Inc. Request for Assignment Assignors: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015243694A 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido(4,5-e)indolizines Active AU2015243694B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207.4 2015-01-30
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
AU2015243694A1 AU2015243694A1 (en) 2016-11-03
AU2015243694B2 true AU2015243694B2 (en) 2019-01-17

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015243694A Active AU2015243694B2 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido(4,5-e)indolizines

Country Status (16)

Country Link
US (3) USRE50082E1 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129374B1 (en) * 2014-04-07 2018-12-19 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
CN114592061A (zh) 2015-04-17 2022-06-07 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
US10758530B2 (en) * 2016-02-19 2020-09-01 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
MA45189A (fr) 2016-06-07 2019-04-10 Jacobio Pharmaceuticals Co Ltd Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
HRP20241239T1 (hr) 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
JP2024546977A (ja) * 2021-12-15 2024-12-26 シルラジェン，インコーポレイテッド 新生物疾患の処置方法
WO2023113477A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP4448017A4 (en) * 2021-12-15 2025-12-24 Sillajen Inc PHARMACEUTICAL COMPOSITIONS CONTAINING MODIFIED BETA-CYCLODEXTRINS
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002243A (es) * 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
OA13170A (en) 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
EP2424868B1 (en) 2009-04-29 2018-01-10 Nerviano Medical Sciences S.r.l. Cdk inhibitor salts
CN102470136B (zh) 2009-07-29 2013-12-25 内尔维阿诺医学科学有限公司 Plk 抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
EP3129374B1 (en) * 2014-04-07 2018-12-19 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Also Published As

Publication number Publication date
HUE043108T2 (hu) 2019-07-29
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
RU2692479C2 (ru) 2019-06-25
ES2716165T3 (es) 2019-06-10
DK3129374T3 (en) 2019-04-08
CN106132963A (zh) 2016-11-16
MX368767B (es) 2019-10-15
KR102432420B1 (ko) 2022-08-17
BR112016022342B1 (pt) 2022-10-04
JP6518690B2 (ja) 2019-05-22
BR112016022342A2 (pt) 2017-08-15
AU2015243694A1 (en) 2016-11-03
EP3129374A1 (en) 2017-02-15
RU2016141405A3 (enExample) 2018-10-02
CN106132963B (zh) 2019-08-06
US9856258B2 (en) 2018-01-02
PL3129374T3 (pl) 2019-07-31
BR112016022342A8 (pt) 2021-07-20
EP3129374B1 (en) 2018-12-19
RU2016141405A (ru) 2018-05-07
CA2944610C (en) 2024-01-09
MX2016012997A (es) 2016-12-07
CA2944610A1 (en) 2015-10-15
KR20170013866A (ko) 2017-02-07
PT3129374T (pt) 2019-03-25
JP2017510595A (ja) 2017-04-13
USRE48974E1 (en) 2022-03-15
USRE50082E1 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
AU2015243694B2 (en) (5,6-dihydro)pyrimido(4,5-e)indolizines
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
AU2017286380B2 (en) Azabenzimidazole derivatives as PI3K beta inhibitors
CN110372720B (zh) 一类激酶抑制剂
JP2025526419A (ja) グルタミニル－ペプチドシクロトランスフェラーゼ及びグルタミニル－ペプチドシクロトランスフェラーゼ様タンパク質の阻害剤としてのピペリジニルピリジニルカルボニトリル誘導体
KR101739003B1 (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
CN114206883A (zh) 氧代吡啶稠环衍生物及包含该衍生物的药物组合物
EP2935272A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
US20230348462A1 (en) Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN117693503A (zh) 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
EP4373816A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
CN109020981A (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
KR20210108433A (ko) 티에노피리디논 화합물
JP6522502B2 (ja) Ｗｎｔシグナル阻害剤
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5，6-二氢)嘧啶并[4，5-e]吲嗪
TW202448895A (zh) 作為egfr抑制劑之大環胺基吡啶化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SILLAJEN INC.

Free format text: FORMER OWNER(S): NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.